Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 210

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 210
---
 Initial Note, the “Notes”).

On August 12, 2024, the
Company and JAK consummated the Initial Closing. The Initial Note sold to JAK in connection with the Securities Purchase Agreement bears
an interest rate of % per annum and is convertible into the Company’s Class A Shares as follows: the Conversion Amount (as
defined below) into validly issued, fully paid and non-assessable Class A at the Conversion Rate determined by dividing the aggregate
of the principal sum plus the interest rates (including late interest charges, if any) and the Make-Whole Amount, if any, by conversion
price of $.

<div align='center'>F-11</div>

At the Initial Closing,
the Company also sold to JAK a Series A Warrant to purchase Class A Shares and a Series B Warrant to purchase Class
B Shares subject to Reverse Stock Split adjustments.

Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with certain holders of its convertible
promissory notes (the “Existing Notes” and each of such amendment and exchange agreements, “Amendment and Exchange
Agreement”), pursuant to which the Company will exchange the Existing Notes by issuing, among other things, (i) senior convertible
notes in the aggregate principal amount of $ (the “Exchange Notes”) and (b) a series of warrants to initially acquire
up to a certain number of ordinary shares to the holders of the Existing Notes set forth therein or in the Amendment and Exchange Agreement
(the “Exchange Warrants”)

On August 28, 2024, the
Company consummated the second tranche of its debt financing under the terms of the Securities Purchase Agreement. At the closing of
the second tranche, the Company sold to JAK Opportunities VI LLC (“JAK”) a senior convertible note (the “Note”)
in the principal amount of $.

On November 11, 2024, the
Company consummated the third tranche of its debt financing under the terms of the Securities Purchase Agreement (“SPA”)
referenced in the current report on Form 6-K filed with the United States Securities and Exchange Commission (the “SEC”)
on August 16, 2024. The Form 6-K filed with the SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of
the SPA, the Company may elect at the second additional mandatory closing to sell and the institutional investor